Alan Mendelson's most recent trade in Paratek Pharmaceuticals Inc. was a trade of 98,750 Common Stock done . Disclosure was reported to the exchange on Aug. 8, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Paratek Pharmaceuticals Inc. | Alan Mendelson | President & Chief Commercial | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Aug 2023 | 98,750 | 750,034 (1%) | 0% | 0 | Common Stock | |
| Paratek Pharmaceuticals Inc. | Alan Mendelson | President & Chief Commercial | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Dec 2022 | 22,500 | 658,034 (1%) | 0% | 0 | Common Stock | |
| Paratek Pharmaceuticals Inc. | Alan Mendelson | President & Chief Commercial | Sale of securities on an exchange or to another person at price $ 1.99 per share. | 20 Dec 2022 | 6,750 | 651,284 (1%) | 0% | 2.0 | 13,433 | Common Stock |
| Paratek Pharmaceuticals Inc. | Alan Mendelson | President & Chief Commercial | Sale of securities on an exchange or to another person at price $ 1.96 per share. | 12 Dec 2022 | 6,253 | 635,534 (1%) | 0% | 2.0 | 12,256 | Common Stock |
| Paratek Pharmaceuticals Inc. | Alan Mendelson | President & Chief Commercial | Sale of securities on an exchange or to another person at price $ 1.98 per share. | 12 Dec 2022 | 3,820 | 641,787 (1%) | 0% | 2.0 | 7,564 | Common Stock |
| Paratek Pharmaceuticals Inc. | Alan Mendelson | President & Chief Commercial | Sale of securities on an exchange or to another person at price $ 3.47 per share. | 28 Oct 2022 | 4,563 | 645,607 (1%) | 0% | 3.5 | 15,834 | Common Stock |
| Paratek Pharmaceuticals Inc. | Alan Mendelson | President & Chief Commercial | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Oct 2022 | 15,000 | 650,170 (1%) | 0% | 0 | Common Stock | |
| Paratek Pharmaceuticals Inc. | Alan Mendelson | President & Chief Commercial | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Aug 2022 | 71,591 | 635,170 (1%) | 0% | 0 | Common Stock | |
| Paratek Pharmaceuticals Inc. | Alan Mendelson | President & Chief Commercial | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2022 | 101,250 | 563,579 (1%) | 0% | 0 | Common Stock | |
| Paratek Pharmaceuticals Inc. | Alan Mendelson | President & Chief Commercial | Sale of securities on an exchange or to another person at price $ 4.27 per share. | 13 Dec 2021 | 22,624 | 462,329 (1%) | 0% | 4.3 | 96,604 | Common Stock |
| Paratek Pharmaceuticals Inc. | Alan Mendelson | President & Chief Commercial | Sale of securities on an exchange or to another person at price $ 4.37 per share. | 13 Dec 2021 | 10,946 | 484,953 (1%) | 0% | 4.4 | 47,834 | Common Stock |
| Paratek Pharmaceuticals Inc. | Alan Mendelson | President & Chief Commercial | Sale of securities on an exchange or to another person at price $ 4.42 per share. | 13 Dec 2021 | 6,422 | 494,899 (1%) | 0% | 4.4 | 28,385 | Common Stock |
| Paratek Pharmaceuticals Inc. | Alan Mendelson | President & Chief Commercial | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2021 | 37,500 | 512,296 (1%) | 0% | 0 | Common Stock | |
| Paratek Pharmaceuticals Inc. | Alan Mendelson | President & Chief Commercial | Sale of securities on an exchange or to another person at price $ 5.12 per share. | 16 Aug 2021 | 10,975 | 501,321 (1%) | 0% | 5.1 | 56,192 | Common Stock |
| Paratek Pharmaceuticals Inc. | Alan Mendelson | President & Chief Commercial | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2021 | 42,955 | 491,978 (1%) | 0% | 0 | Common Stock | |
| Paratek Pharmaceuticals Inc. | Alan Mendelson | President & Chief Commercial | Sale of securities on an exchange or to another person at price $ 9.70 per share. | 27 May 2021 | 17,182 | 474,796 (1%) | 0% | 9.7 | 166,665 | Common Stock |
| Coherus Biosciences Inc | Alan C. Mendelson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2021 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) |